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Abstract
Di-2-ethylhexyl adipate (DEHA) is a common plasticizer used in food packaging. At high doses, 
DEHA can cause adverse health effects in rats. Although the potential for human exposure to 
DEHA is high, no DEHA specific biomarkers are identified for human biomonitoring. Using 
human liver microsomes, we investigated the in vitro phase I metabolism of DEHA and its 
hydrolytic metabolite mono-2-ethylhexyl adipate (MEHA) and, for comparison purposes, of the 
analogous di-2-ethylhexyl phthalate (DEHP) and its hydrolytic metabolite mono-2-ethylhexyl 
phthalate. We unequivocally identified MEHA, a DEHA specific biomarker, and adipic acid, a 
nonspecific biomarker, using authentic standards. On the basis of their mass spectrometric 
fragmentation patterns, we tentatively identified two other DEHA specific metabolites: mono-2-
ethylhydroxyhexyl adipate (MEHHA) and mono-2-ethyloxohexyl adipate (MEOHA), analogous 
to the oxidative metabolites of DEHP. Interestingly, although adipic acid was the major in vitro 
metabolite of DEHA, the analogous phthalic acid was not the major in vitro metabolite of DEHP. 
Our preliminary data for 144 adults with no known exposure to DEHA suggests that adipic acid is 
also the main in vivo urinary metabolite, while MEHA, MEHHA, and MEOHA are only minor 
metabolites. Therefore, the use of these specific metabolites for assessing the exposure of DEHA 
may be limited to highly exposed populations.
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Di-2-ethylhexyl adipate (DEHA; hexanedioic acid, di-2-ethylhexyl ester) is used extensively 
as a plasticizer in flexible polyvinyl chloride (PVC) and food contact films.1 The migration 
of DEHA from PVC film into food content2,3 is thought to be a major source of human 
exposure among the general population.4 Results from a recent study5 based on duplicate 
diet samples suggest that median dietary intake of DEHA among a group of German adults 
is 0.67 μg/kg bw, well below the tolerable daily intake of 280 μg/kg bw.5
In humans and rats, after oral administration, DEHA is hydrolyzed first to mono-2-
ethylhexyl adipate (MEHA), which can be further metabolized and rapidly excreted in urine, 
mainly as adipic acid.4,6 Exposure of Harlan/ICR albino Swiss mice after a single 
intraperitoneal dose of 10 mL/kg DEHA before the 8 week mating period caused a reduced 
percentage of pregnancies and an increased number of fetal deaths.7 At doses at or above 
1,000 mg/kg, DEHA disturbed ovulation and follicle growth in rats.8 Animal 
carcinogenicity data are limited,9 and DEHA is not classifiable as to its carcinogenicity to 
humans.1
No human data are available on any potential toxicity associated with DEHA exposure, but 
in order to study the potential health effects of human exposure to DEHA at environmental 
levels, identification of sensitive and specific biomarkers is necessary. Previously, five 
metabolites of DEHA, namely, 2-ethylhexanoic acid, 2-ethylhexanol, 2-ethyl-5-
hydroxyhexanoic acid, 2-ethylhexane dioic acid, and 2-ethyl-5-ketohexanoic acid were 
identified in the urine of six adult volunteers orally administered with 46 mg of deuterium 
labeled-DEHA10 and accounted for 12.1% of the administered DEHA dose.10 However, 
these metabolites are unsuitable for human exposure assessment because they are 
nonspecific biomarkers of DEHA that can be formed from any esters containing a 2-
ethylhexyl side chain, including di-2-ethylhexyl phthalate (DEHP), another widely used 
plasticizer. Metabolism of DEHP formed mono-2-ethylhexyl phthalate (MEHP) and several 
DEHP specific metabolic products that can be used as biomarkers of DEHP exposure, 
namely, mono-2-ethyl-5-oxohexyl phthalate (MEOHP), mono-2-ethyl-5-hydroxyhexyl 
phthalate (MEHHP), and mono-2-ethyl-5-carboxypentyl phthalate (MECPP).11–13 We 
hypothesized that DEHA may produce similar metabolites and that they could be used as 
DEHA specific exposure biomarkers.
For the present study, we used online solid phase extraction (SPE) followed by high 
performance liquid chromatography (HPLC) and mass spectrometry to investigate in vitro 
phase I metabolism of DEHA and DEHP by human liver microsomes in order to identify 
potential DEHA specific exposure biomarkers for human biomonitoring and compare them 
to the known DEHP metabolites. Because DEHA is rapidly hydrolyzed to MEHA that may 
be further metabolized before its elimination in urine, much like MEHP, we also 
investigated the in vitro metabolism of MEHA and MEHP.
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MEHA was purchased from CanSyn (Ontario, Canada). All phthalate metabolites and their 
stable-isotope labeled analogues, 13C6-DEHA and 13C6-MEHA, were purchased from 
Cambridge Isotope Laboratories (Andover, MA, USA). Adipic acid, DEHA, and DEHP 
were purchased from SigmaAldrich (St. Louis, MO, USA). All reagents, solvents, and 
standard materials were used without further purification.
Human Samples
The urine samples analyzed for this study (N = 144) were archived samples (stored at −70 
°C) collected anonymously in Atlanta, GA between 2000 and 2013 from a demographically 
diverse group of U.S. male and female adults with no known DEHA exposure. No personal 
information from the subjects was available. Samples were collected between 8:00 a.m. and 
5:00 p.m. and were not necessarily first-morning voids. The Centers for Disease Control and 
Prevention (CDC) Institutional Review Board approved the collection of the urine for the 
development and validation of analytical methods at the CDC. A waiver of informed 
consent was requested under 45 CFR 46.116(d).
In Vitro Metabolism
We incubated DEHA (273 μg/mL), 13C6-DEHA (200 μg/mL), MEHA (234 μg/mL), 
or 13C6-MEHA (200 μg/mL) separately with human liver microsome homogenates (BD 
Gentest, Woburn, MA, USA). Each standard solution (50 μL) was mixed with pH 7.4 
phosphate buffer (0.1M, 8 mL), water (1 mL), NADPH regenerating solution A (500 μL, BD 
Gentest), NADPH regenerating solution B (100 μL, BD Gentest), and male human liver 
microsomes (200 μL, 50 donor pooled-20 mg/mL, BD Gentest) in a glass beaker. The 
contents were gently mixed and placed on a rotary shaker in an incubator (Fisher Scientific, 
Hampton, NH, USA) at 37 °C for 5 h. After incubation, each microsomal suspension was 
transferred into a microcentrifuge tube and centrifuged at 12,500 rpm for 20 min on an 
Avanti high performance centrifuge (Beckman Coulter, Inc., Brea, CA, USA). The 
supernatant was then transferred into an autosampler vial for metabolite identification 
following the procedure described below.
For the comparison study with DEHP and MEHP, we used the above for solutions 
containing (A) DEHP (100 μM) and DEHA (100 μM), and (B) MEHP (10 μM) and MEHA 
(10 μM) incubated with human liver microsome homogenates for 24 h for solution A and 12 
h for solution B. Controls did not contain either microsomes or DEHA/MEHA (or DEHP/
MEHP). At several time intervals, 100 μL aliquots (N = 3) were withdrawn into 
microcentrifuge tubes containing acetonitrile (200 μL) and an internal standard solution (100 
μL) prepared with 13C2-phthalic acid, 13C4-MEHP, D4-mono-2-ethyl-5-oxohexyl phthalate 
(D4-MEOHP), D4-mono-2-ethyl-5-hydrox-yhexyl phthalate (D4-MEHHP), D4-mono-2-
ethyl-5-carboxypentyl phthalate (D4-MECPP), and 13C6-MEHA in 10% aqueous 
acetonitrile. The contents in the microcentrifuge tubes were vortex mixed and centrifuged at 
12,500 rpm for 20 min on an Avanti high performance centrifuge. The supernatant was 
transferred into autosampler vials for the quantification of DEHP and DEHA metabolites. 
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All stock standard solutions were prepared in acetonitrile. The dilutions of stock solutions 
were made in deionized water.
Identification of in Vitro Metabolites
Details on the HPLC gradient for the separation of DEHA and DEHP metabolites and the 
method for online SPE are presented elsewhere.14,15 Briefly, metabolites in the supernatant 
of the human liver microsomal homogenate (500 μL), obtained after incubating for 5 h with 
DEHA and MEHA, were extracted using online SPE on a Chromolith RP-18 precolumn 
(Merck KGaA, Darmstadt, Germany), resolved on a Betasil phenyl HPLC column (3 μM, 
2.1 mm × 25 mm, ThermoFisher Scientific, San Jose, CA, USA) using a water/acetonitrile 
gradient program and detected by mass spectrometry on a TSQ Vantage AM triple 
quadrupole mass spectrometer (ThermoFisher Scientific, San Jose, CA, USA).
All ions on Q1 were scanned from m/z = 125 to m/z = 400 in negative ion mode. The 
fragmentation patterns of electrospray ionization (ESI) mass spectra of the major peaks were 
analyzed to identify potential DEHA metabolites (Table 1). ESI Q1 full scan produced 
multiple peaks. Metabolites unique to DEHA were identified by comparing the mass 
transitions of the peaks resulting from DEHA or MEHA to their isotopically labeled 
analogues. Product ion scans were performed only for the peaks with a mass difference (Δm) 
of 6 between the DEHA or MEHA metabolites and their 13C6-analogues. All common peaks 
with similar m/z values were excluded from further evaluation. The phthalate metabolites 
phthalic acid, MEHP, MEHHP, MECPP, and MEOHP were identified using authentic 
standards.
Quantification of DEHP and DEHA Metabolites
Adipic acid, MEHA, MEHP, MEHHP, MECPP, and MEOHP were quantified using 
authentic standards; mono-2-ethyloxohexyl adipate (MEOHA) and mono-2-
ethylhydroxyhexyl adipate (MEHHA) were quantified using the MEHA calibration curve. 
Isotope-dilution quantification was used for all phthalate metabolites. 13C6-MEHA was used 
as the internal standard for all adipate metabolites (Table 1). Because all coeluting isomeric 
metabolites of DEHA produced similar fragmentation patterns, no attempts were made to 
characterize the individual isomers of MEHHA and MEOHA. Instead, all coeluting isomers 
were quantified together. The limits of detection (LOD) for adipic acid, MEHHA, MEOHA, 
and MEHA were set as the lowest detectable standard (0.5 ng/mL); for the phthalate 
metabolites, the LODs were 0.5 ng/mL (MEHP) and 0.2 ng/mL (MEHHP and MEOHP).
To determine the urinary concentrations of DEHA metabolites in the human samples (N = 
144), 100 μL of urine was spiked with the internal standard solution containing 13C6-
MEHA. The target metabolites, after enzymatic hydrolysis with β-glucuronidase, were 
extracted by online solid phase extraction using a Chromolith RP-18 precolumn, 
chromatographically resolved using a gradient program, and detected by ESI-tandem mass 
spectrometry as described.14 The previous method was modified to quantify DEHA 
metabolites (Table 1). The mobile phase contained 0.1% acetic acid in water and 0.1% 
acetic acid in acetonitrile.
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Five nonspecific metabolites of DEHA have been identified previously in the urine of six 
adult volunteers administered with deuterium labeled DEHA.4 We used in vitro metabolism 
to identify specific biomarkers of DEHA. Full scan analysis in negative ion mode from m/z 
= 125 to m/z = 400 of the human liver microsomal supernatant after 5 h of incubation with 
DEHA resulted in six unique peaks at different retention times (Figure 1). Two of these 
metabolites, adipic acid (m/z = 145, RT = 3.9 min) and MEHA (m/z = 257, RT = 24.2 min), 
were positively identified using authentic standards. Attempts to identify the two 
metabolites with m/z = 159 (RT = 3.96 min) and 173 (RT = 5.3 min) were not made because 
they are nonspecific metabolites of DEHA derived from chemical modifications of the 
adipic acid backbone. In the absence of authentic standards and based on their fragmentation 
patterns, we tentatively identified MEOHA (RT = 11.2 min, m/z = 271) and MEHHA (RT = 
10–12 min, m/z = 273). In vitro metabolism of 13C6-DEHA and 13C6-MEHA formed 
analogous metabolites, 13C6-MEHHA and 13C6-MEOHA, further supporting the identity of 
these oxidative products (Figure 2). Interestingly, MEHHA and MEOHA eluted as two 
separate clusters of peaks, likely due to multiple oxidation sites in the 2-ethyl hexyl side 
chain and the adipic acid backbone that produced similar fragmentation patterns (Figure 1). 
We previously observed similar metabolite clusters for other plasticizers, including di-
isononyl phthalate and 1,2-cyclohexane dicarboxylic acid, diisononyl ester.15–18 Because all 
coeluting isomers of MEHHA and MEOHA are valid biomarkers of exposure to DEHA and 
similar in structure with different oxidation sites, we did not attempt to separate the isomers 
and included them together to facilitate their detection.
MEHHA and MEOHA are analogous to MEHHP and MEOHP, oxidative metabolites of 
DEHP;11,13 therefore, we also evaluated the in vitro metabolism of DEHP. Our data suggest 
that the first products formed, the hydrolytic monoesters MEHA (from DEHA) and MEHP 
(from DEHP), are further metabolized to the diacids (adipic acid or phthalic acid, 
respectively) and other oxidative products (Figure 3). Adipic acid was the major metabolite 
of DEHA/MEHA after 24 h/12 h of incubation with human liver microsomes, but phthalic 
acid was only a minor product of the DEHP/MEHP metabolism (Figure 3). In vitro 
metabolism of MEHP by human liver microsomes was faster (t1/2 = 0.56 h) compared to 
MEHA (t1/2 = 0.77 h). We did not detect MEHP and MEHA after 8 h of incubation with 
human liver microsomes (Figure 3). Also, both DEHA and DEHP formed the corresponding 
oxo metabolite (MEOHA and MEOHP, respectively); MEOHA was not detectable until 4 h 
after incubation. By contrast, we detected MEOHP immediately upon the incubation of 
DEHP and MEHP with human liver microsomes. Although MECPP is present as a major 
urinary oxidative metabolite of DEHP in humans,12,19 under our experimental conditions, 
MECPP was a minor in vitro metabolite (Figure 3). Similarly, we did not detect mono-2-
ethyl-5-carboxypentyl adipate from the in vitro metabolism of DEHA. These findings 
suggest important differences in the in vitro metabolism of DEHA/MEHA and DEHP/
MEHP.
In 144 urine samples from a group of US adults with no known exposure to DEHA, we 
detected adipic acid in all of the samples (median 313 nM (45.7 ng/mL); the maximum was 
77,664 nM (11,333 ng/mL), whereas MEHHA, MEOHA, and MEHA were detectable in 
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fewer than 20% of the samples and at lower concentration ranges: MEHA, <LOD-165 nM 
(LOD-42.5 ng/mL); MEHHA, <LOD-87 nM (LOD-23.9 ng/mL); and MEOHA, <LOD-38 
nM (LOD-10.4 ng/mL). The urinary concentrations of MEHHA and MEOHA in these 
samples correlated well (r = 0.83, p < 0.01); however, these concentrations did not correlate 
with the concentrations of adipic acid. Adipic acid is not a unique biomarker for DEHA but 
the final hydrolytic metabolite of all adipates, including dibutyl adipate and diisononyl 
adipate. Further, adipic acid is used as a food additive.20 The lack of correlation between the 
urinary concentrations of adipic acid and the specific DEHA metabolites suggest additional 
sources for urinary adipic acid besides DEHA in the group of adults examined.
In summary, our study suggests that measuring the urinary concentrations of DEHA specific 
metabolites would be a suitable approach for assessing DEHA background exposure in 
humans. However, in contrast to the phthalate plasticizer DEHP, because DEHA appears to 
be metabolized mainly to the nonspecific metabolite adipic acid, MEHA, MEHHA, and 
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Chromatographic separation of DEHA metabolites detected in a human liver microsomes 
suspension of DEHA after 5 h of incubation at 37 °C. MEOHA, mono-2-ethyl oxohexyl 
adipate; MEHHA, mono-2-ethylhydroxyhexyl adipate; MEHA, mono-2-ethyl-hexyl adipate.
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Mass spectrometric fragmentation of (A) adipic acid, (B) MEOHA, (C) MEHA, and (D) 
MEHHA formed after in vitro phase I metabolism of DEHA (left) and 13C6-DEHA (right) 
using human liver microsomes. Structures shown are for only one of the potential isomers.
Silva et al. Page 9














Time dependent formation of phase I in vitro metabolites of MEHP (A), MEHA (B), DEHP 
(C), and DEHA (D) with human liver microsomes. Error bars represent the standard 
deviation (N = 3). MEHHA and MEOHA were quantified using MEHA. DEHA and DEHP 
levels were not monitored.
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Table 1
Mass Spectrometric Specifications Used for Measuring the Metabolites of Di-2-ethylhexyl Adipate (DEHA)a
DEHA metabolite
m/z
CE (eV) S-Lens (V)precursor productb
adipic acid 145 83 13 53
mono-2-ethylhexyl adipate (MEHA) 257 83 15 72
mono-2-ethylhydroxyhexyl adipate (MEHHA)c 273 83 15 72
mono-2-ethyloxohexyl adipate (MEOHA)c 271 83 15 72
a
Structures shown are for only one of the potential isomers.
b
Optimized for the most abundant peak.
c
Multiple isomeric metabolites.
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